A detailed history of Altium Capital Management LP transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Altium Capital Management LP holds 72,000 shares of PCVX stock, worth $6.6 Million. This represents 2.9% of its overall portfolio holdings.

Number of Shares
72,000
Holding current value
$6.6 Million
% of portfolio
2.9%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$70.52 - $117.12 $5.08 Million - $8.43 Million
72,000 New
72,000 $8.22 Million
Q4 2022

Feb 14, 2023

BUY
$20.58 - $47.95 $884,939 - $2.06 Million
43,000 New
43,000 $2.06 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.43B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Altium Capital Management LP Portfolio

Follow Altium Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Altium Capital Management LP with notifications on news.